What's Wrong With Iovance Biotherapeutics Stock?

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel) as a treatment option for patients with unresectable or metastatic melanoma.Since hitting a high of more than $18 last February, however, the stock has been declining steadily. And over the past six months, it has fallen by 32%. Entering trading this week, shares of Iovance are worth a little over $6 -- just a fraction of the highs they reached when regulators approved Amtagvi.What is wrong with Iovance and why isn't it trading at a higher valuation? Could this be a great buying opportunity for investors, or is the healthcare stock in danger of falling even lower this year?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool